The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Kidney Neoplasms , 38 publications
- Carcinoma, Renal Cell , 28 publications
- Nephrectomy , 20 publications
- Prostatic Neoplasms , 17 publications
Research activity
Active clinical trials
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
93 publications
2021
Association between nuclear grade of renal cell carcinoma and the aorta-lesion-attenuation-difference.
Abdominal radiology (New York)
PubMed • Publisher's site2021
Hyal2 Expression in Tumor-Associated Myeloid Cells Mediates Cancer-Related Inflammation in Bladder Cancer.
Cancer research
PubMed • Publisher's site2021
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
The Lancet. Oncology
PubMed • Publisher's site2021
Patient and Procedural Determinants of Postoperative Pain Trajectories.
Anesthesiology
PubMed • Publisher's site2021
Predicting long-term postsurgical pain by examining the evolution of acute pain.
European journal of pain (London, England)
PubMed • Publisher's site